# Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

> **NCT00795730** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Alzheimer Disease
- Healthy Subjects

## Interventions

- **DRUG:** NSA-789
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00795730
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00795730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00795730, "Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT00795730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*